Predictmedix Inc.
Predictmedix Inc. (PMEDF) Stock Competitors & Peer Comparison
See (PMEDF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PMEDF | $0.04 | -14.80% | 7.9M | -1.90 | -$0.02 | N/A |
| SMMNY | $24.40 | -1.93% | 109.8B | 21.78 | $1.12 | +1.48% |
| SEMHF | $51.25 | +1.49% | 57.2B | 22.88 | $2.24 | +2.34% |
| RYLPF | $33.00 | +0.30% | 31.4B | 29.20 | $1.13 | +2.90% |
| SONVY | $50.15 | -0.99% | 15.1B | 22.37 | $2.26 | +2.13% |
| SONVF | $249.59 | -1.25% | 14.9B | 22.05 | $11.32 | +2.15% |
| SNNUF | $16.59 | +0.00% | 14.1B | 29.62 | $0.56 | +2.30% |
| CHEOF | $180.67 | +0.00% | 11.8B | 43.96 | $4.11 | +1.53% |
| CHEOY | $68.95 | -1.49% | 9B | 36.85 | $1.87 | +1.87% |
| WILYY | $13.84 | -2.05% | 6.1B | 15.54 | $0.89 | N/A |
Stock Comparison
PMEDF vs SMMNY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, SMMNY has a market cap of 109.8B. Regarding current trading prices, PMEDF is priced at $0.04, while SMMNY trades at $24.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas SMMNY's P/E ratio is 21.78. In terms of profitability, PMEDF's ROE is +1.24%, compared to SMMNY's ROE of +0.11%. Regarding short-term risk, PMEDF is more volatile compared to SMMNY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check SMMNY's competition here
PMEDF vs SEMHF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, SEMHF has a market cap of 57.2B. Regarding current trading prices, PMEDF is priced at $0.04, while SEMHF trades at $51.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas SEMHF's P/E ratio is 22.88. In terms of profitability, PMEDF's ROE is +1.24%, compared to SEMHF's ROE of +0.11%. Regarding short-term risk, PMEDF is more volatile compared to SEMHF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check SEMHF's competition here
PMEDF vs RYLPF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, RYLPF has a market cap of 31.4B. Regarding current trading prices, PMEDF is priced at $0.04, while RYLPF trades at $33.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas RYLPF's P/E ratio is 29.20. In terms of profitability, PMEDF's ROE is +1.24%, compared to RYLPF's ROE of +0.08%. Regarding short-term risk, PMEDF is more volatile compared to RYLPF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check RYLPF's competition here
PMEDF vs SONVY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, SONVY has a market cap of 15.1B. Regarding current trading prices, PMEDF is priced at $0.04, while SONVY trades at $50.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas SONVY's P/E ratio is 22.37. In terms of profitability, PMEDF's ROE is +1.24%, compared to SONVY's ROE of +0.20%. Regarding short-term risk, PMEDF is more volatile compared to SONVY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check SONVY's competition here
PMEDF vs SONVF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, SONVF has a market cap of 14.9B. Regarding current trading prices, PMEDF is priced at $0.04, while SONVF trades at $249.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas SONVF's P/E ratio is 22.05. In terms of profitability, PMEDF's ROE is +1.24%, compared to SONVF's ROE of +0.18%. Regarding short-term risk, PMEDF is more volatile compared to SONVF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check SONVF's competition here
PMEDF vs SNNUF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, SNNUF has a market cap of 14.1B. Regarding current trading prices, PMEDF is priced at $0.04, while SNNUF trades at $16.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas SNNUF's P/E ratio is 29.62. In terms of profitability, PMEDF's ROE is +1.24%, compared to SNNUF's ROE of +0.09%. Regarding short-term risk, PMEDF is more volatile compared to SNNUF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check SNNUF's competition here
PMEDF vs CHEOF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CHEOF has a market cap of 11.8B. Regarding current trading prices, PMEDF is priced at $0.04, while CHEOF trades at $180.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CHEOF's P/E ratio is 43.96. In terms of profitability, PMEDF's ROE is +1.24%, compared to CHEOF's ROE of +0.18%. Regarding short-term risk, PMEDF is more volatile compared to CHEOF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CHEOF's competition here
PMEDF vs CHEOY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CHEOY has a market cap of 9B. Regarding current trading prices, PMEDF is priced at $0.04, while CHEOY trades at $68.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CHEOY's P/E ratio is 36.85. In terms of profitability, PMEDF's ROE is +1.24%, compared to CHEOY's ROE of +0.18%. Regarding short-term risk, PMEDF is more volatile compared to CHEOY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CHEOY's competition here
PMEDF vs WILYY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, WILYY has a market cap of 6.1B. Regarding current trading prices, PMEDF is priced at $0.04, while WILYY trades at $13.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas WILYY's P/E ratio is 15.54. In terms of profitability, PMEDF's ROE is +1.24%, compared to WILYY's ROE of +0.16%. Regarding short-term risk, PMEDF is more volatile compared to WILYY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check WILYY's competition here
PMEDF vs GNGBY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, GNGBY has a market cap of 6B. Regarding current trading prices, PMEDF is priced at $0.04, while GNGBY trades at $21.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas GNGBY's P/E ratio is 23.60. In terms of profitability, PMEDF's ROE is +1.24%, compared to GNGBY's ROE of +0.08%. Regarding short-term risk, PMEDF is more volatile compared to GNGBY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check GNGBY's competition here
PMEDF vs WILLF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, WILLF has a market cap of 6B. Regarding current trading prices, PMEDF is priced at $0.04, while WILLF trades at $28.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas WILLF's P/E ratio is 15.78. In terms of profitability, PMEDF's ROE is +1.24%, compared to WILLF's ROE of +0.16%. Regarding short-term risk, PMEDF is more volatile compared to WILLF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check WILLF's competition here
PMEDF vs GNGBF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, GNGBF has a market cap of 5.9B. Regarding current trading prices, PMEDF is priced at $0.04, while GNGBF trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas GNGBF's P/E ratio is 25.25. In terms of profitability, PMEDF's ROE is +1.24%, compared to GNGBF's ROE of +0.08%. Regarding short-term risk, PMEDF is more volatile compared to GNGBF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check GNGBF's competition here
PMEDF vs AMBFF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, AMBFF has a market cap of 3.7B. Regarding current trading prices, PMEDF is priced at $0.04, while AMBFF trades at $13.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas AMBFF's P/E ratio is 42.66. In terms of profitability, PMEDF's ROE is +1.24%, compared to AMBFF's ROE of +0.09%. Regarding short-term risk, PMEDF is more volatile compared to AMBFF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check AMBFF's competition here
PMEDF vs NHNKY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, NHNKY has a market cap of 3.5B. Regarding current trading prices, PMEDF is priced at $0.04, while NHNKY trades at $10.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas NHNKY's P/E ratio is 14.86. In terms of profitability, PMEDF's ROE is +1.24%, compared to NHNKY's ROE of +0.07%. Regarding short-term risk, PMEDF is more volatile compared to NHNKY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check NHNKY's competition here
PMEDF vs AMBBY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, AMBBY has a market cap of 3.3B. Regarding current trading prices, PMEDF is priced at $0.04, while AMBBY trades at $12.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas AMBBY's P/E ratio is 39.19. In terms of profitability, PMEDF's ROE is +1.24%, compared to AMBBY's ROE of +0.09%. Regarding short-term risk, PMEDF is more volatile compared to AMBBY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check AMBBY's competition here
PMEDF vs MCRPF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, MCRPF has a market cap of 2.9B. Regarding current trading prices, PMEDF is priced at $0.04, while MCRPF trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas MCRPF's P/E ratio is -17.44. In terms of profitability, PMEDF's ROE is +1.24%, compared to MCRPF's ROE of -0.27%. Regarding short-term risk, PMEDF is more volatile compared to MCRPF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check MCRPF's competition here
PMEDF vs NHNKF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, NHNKF has a market cap of 2.4B. Regarding current trading prices, PMEDF is priced at $0.04, while NHNKF trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas NHNKF's P/E ratio is 41.86. In terms of profitability, PMEDF's ROE is +1.24%, compared to NHNKF's ROE of +0.07%. Regarding short-term risk, PMEDF is less volatile compared to NHNKF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check NHNKF's competition here
PMEDF vs GGNDF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, GGNDF has a market cap of 2.4B. Regarding current trading prices, PMEDF is priced at $0.04, while GGNDF trades at $16.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas GGNDF's P/E ratio is 23.15. In terms of profitability, PMEDF's ROE is +1.24%, compared to GGNDF's ROE of +0.06%. Regarding short-term risk, PMEDF is more volatile compared to GGNDF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check GGNDF's competition here
PMEDF vs GNNDY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, GNNDY has a market cap of 2.1B. Regarding current trading prices, PMEDF is priced at $0.04, while GNNDY trades at $44.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas GNNDY's P/E ratio is 20.68. In terms of profitability, PMEDF's ROE is +1.24%, compared to GNNDY's ROE of +0.06%. Regarding short-term risk, PMEDF is more volatile compared to GNNDY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check GNNDY's competition here
PMEDF vs DRWKF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, DRWKF has a market cap of 2.1B. Regarding current trading prices, PMEDF is priced at $0.04, while DRWKF trades at $111.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas DRWKF's P/E ratio is 14.68. In terms of profitability, PMEDF's ROE is +1.24%, compared to DRWKF's ROE of +0.08%. Regarding short-term risk, PMEDF is more volatile compared to DRWKF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check DRWKF's competition here
PMEDF vs OSSFF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, OSSFF has a market cap of 2.1B. Regarding current trading prices, PMEDF is priced at $0.04, while OSSFF trades at $4.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas OSSFF's P/E ratio is 24.25. In terms of profitability, PMEDF's ROE is +1.24%, compared to OSSFF's ROE of +0.10%. Regarding short-term risk, PMEDF is more volatile compared to OSSFF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check OSSFF's competition here
PMEDF vs OSSUY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, OSSUY has a market cap of 1.9B. Regarding current trading prices, PMEDF is priced at $0.04, while OSSUY trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas OSSUY's P/E ratio is 22.30. In terms of profitability, PMEDF's ROE is +1.24%, compared to OSSUY's ROE of +0.10%. Regarding short-term risk, PMEDF is more volatile compared to OSSUY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check OSSUY's competition here
PMEDF vs DWRKF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, DWRKF has a market cap of 1.8B. Regarding current trading prices, PMEDF is priced at $0.04, while DWRKF trades at $543.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas DWRKF's P/E ratio is 75.94. In terms of profitability, PMEDF's ROE is +1.24%, compared to DWRKF's ROE of N/A. Regarding short-term risk, PMEDF is more volatile compared to DWRKF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check DWRKF's competition here
PMEDF vs MEDGF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, MEDGF has a market cap of 1.7B. Regarding current trading prices, PMEDF is priced at $0.04, while MEDGF trades at $83.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas MEDGF's P/E ratio is 33.30. In terms of profitability, PMEDF's ROE is +1.24%, compared to MEDGF's ROE of +0.24%. Regarding short-term risk, PMEDF is more volatile compared to MEDGF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check MEDGF's competition here
PMEDF vs STSEY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, STSEY has a market cap of 1.5B. Regarding current trading prices, PMEDF is priced at $0.04, while STSEY trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas STSEY's P/E ratio is 17.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to STSEY's ROE of +0.07%. Regarding short-term risk, PMEDF is more volatile compared to STSEY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check STSEY's competition here
PMEDF vs DGWPF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, DGWPF has a market cap of 1.4B. Regarding current trading prices, PMEDF is priced at $0.04, while DGWPF trades at $72.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas DGWPF's P/E ratio is 9.45. In terms of profitability, PMEDF's ROE is +1.24%, compared to DGWPF's ROE of +0.08%. Regarding short-term risk, PMEDF is more volatile compared to DGWPF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check DGWPF's competition here
PMEDF vs ELEAF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ELEAF has a market cap of 1.3B. Regarding current trading prices, PMEDF is priced at $0.04, while ELEAF trades at $16.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ELEAF's P/E ratio is 21.28. In terms of profitability, PMEDF's ROE is +1.24%, compared to ELEAF's ROE of +0.09%. Regarding short-term risk, PMEDF is less volatile compared to ELEAF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check ELEAF's competition here
PMEDF vs VTRLY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, VTRLY has a market cap of 1.3B. Regarding current trading prices, PMEDF is priced at $0.04, while VTRLY trades at $9.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas VTRLY's P/E ratio is -2.29. In terms of profitability, PMEDF's ROE is +1.24%, compared to VTRLY's ROE of -0.42%. Regarding short-term risk, PMEDF is more volatile compared to VTRLY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check VTRLY's competition here
PMEDF vs FDMDF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, FDMDF has a market cap of 1.2B. Regarding current trading prices, PMEDF is priced at $0.04, while FDMDF trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas FDMDF's P/E ratio is -21.90. In terms of profitability, PMEDF's ROE is +1.24%, compared to FDMDF's ROE of -0.48%. Regarding short-term risk, PMEDF is more volatile compared to FDMDF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check FDMDF's competition here
PMEDF vs MDRSF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, MDRSF has a market cap of 1.2B. Regarding current trading prices, PMEDF is priced at $0.04, while MDRSF trades at $100.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas MDRSF's P/E ratio is -1666.67. In terms of profitability, PMEDF's ROE is +1.24%, compared to MDRSF's ROE of -0.00%. Regarding short-term risk, PMEDF is more volatile compared to MDRSF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check MDRSF's competition here
PMEDF vs LFTSF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, LFTSF has a market cap of 1B. Regarding current trading prices, PMEDF is priced at $0.04, while LFTSF trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas LFTSF's P/E ratio is 23.35. In terms of profitability, PMEDF's ROE is +1.24%, compared to LFTSF's ROE of +0.02%. Regarding short-term risk, PMEDF is more volatile compared to LFTSF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check LFTSF's competition here
PMEDF vs XVIPF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, XVIPF has a market cap of 740.9M. Regarding current trading prices, PMEDF is priced at $0.04, while XVIPF trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas XVIPF's P/E ratio is 261.33. In terms of profitability, PMEDF's ROE is +1.24%, compared to XVIPF's ROE of +0.01%. Regarding short-term risk, PMEDF is more volatile compared to XVIPF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check XVIPF's competition here
PMEDF vs IOBCF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, IOBCF has a market cap of 533.7M. Regarding current trading prices, PMEDF is priced at $0.04, while IOBCF trades at $18.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas IOBCF's P/E ratio is 26.78. In terms of profitability, PMEDF's ROE is +1.24%, compared to IOBCF's ROE of +0.15%. Regarding short-term risk, PMEDF is more volatile compared to IOBCF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check IOBCF's competition here
PMEDF vs AVMR Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, AVMR has a market cap of 494.2M. Regarding current trading prices, PMEDF is priced at $0.04, while AVMR trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas AVMR's P/E ratio is -18.34. In terms of profitability, PMEDF's ROE is +1.24%, compared to AVMR's ROE of -0.68%. Regarding short-term risk, PMEDF is more volatile compared to AVMR. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check AVMR's competition here
PMEDF vs CALZF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CALZF has a market cap of 472.9M. Regarding current trading prices, PMEDF is priced at $0.04, while CALZF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CALZF's P/E ratio is 68.45. In terms of profitability, PMEDF's ROE is +1.24%, compared to CALZF's ROE of +0.17%. Regarding short-term risk, PMEDF is more volatile compared to CALZF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CALZF's competition here
PMEDF vs BRSYF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, BRSYF has a market cap of 451.7M. Regarding current trading prices, PMEDF is priced at $0.04, while BRSYF trades at $11.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas BRSYF's P/E ratio is 72.13. In terms of profitability, PMEDF's ROE is +1.24%, compared to BRSYF's ROE of +0.09%. Regarding short-term risk, PMEDF is more volatile compared to BRSYF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check BRSYF's competition here
PMEDF vs CSSPF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CSSPF has a market cap of 384.5M. Regarding current trading prices, PMEDF is priced at $0.04, while CSSPF trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CSSPF's P/E ratio is 92.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to CSSPF's ROE of +0.08%. Regarding short-term risk, PMEDF is less volatile compared to CSSPF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check CSSPF's competition here
PMEDF vs CLVSF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CLVSF has a market cap of 378M. Regarding current trading prices, PMEDF is priced at $0.04, while CLVSF trades at $15.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CLVSF's P/E ratio is 22.01. In terms of profitability, PMEDF's ROE is +1.24%, compared to CLVSF's ROE of +0.18%. Regarding short-term risk, PMEDF is more volatile compared to CLVSF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CLVSF's competition here
PMEDF vs CYBQY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CYBQY has a market cap of 362M. Regarding current trading prices, PMEDF is priced at $0.04, while CYBQY trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CYBQY's P/E ratio is -203.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to CYBQY's ROE of -0.00%. Regarding short-term risk, PMEDF is more volatile compared to CYBQY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CYBQY's competition here
PMEDF vs HYBT Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, HYBT has a market cap of 361.4M. Regarding current trading prices, PMEDF is priced at $0.04, while HYBT trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas HYBT's P/E ratio is N/A. In terms of profitability, PMEDF's ROE is +1.24%, compared to HYBT's ROE of +0.02%. Regarding short-term risk, PMEDF is more volatile compared to HYBT. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check HYBT's competition here
PMEDF vs DMTRF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, DMTRF has a market cap of 284.9M. Regarding current trading prices, PMEDF is priced at $0.04, while DMTRF trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas DMTRF's P/E ratio is -118.50. In terms of profitability, PMEDF's ROE is +1.24%, compared to DMTRF's ROE of +0.00%. Regarding short-term risk, PMEDF is less volatile compared to DMTRF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check DMTRF's competition here
PMEDF vs CYBQF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CYBQF has a market cap of 261.5M. Regarding current trading prices, PMEDF is priced at $0.04, while CYBQF trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CYBQF's P/E ratio is -196.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to CYBQF's ROE of -0.00%. Regarding short-term risk, PMEDF is less volatile compared to CYBQF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check CYBQF's competition here
PMEDF vs HTLZF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, HTLZF has a market cap of 245.1M. Regarding current trading prices, PMEDF is priced at $0.04, while HTLZF trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas HTLZF's P/E ratio is -159.01. In terms of profitability, PMEDF's ROE is +1.24%, compared to HTLZF's ROE of -0.01%. Regarding short-term risk, PMEDF is more volatile compared to HTLZF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check HTLZF's competition here
PMEDF vs EAPIF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, EAPIF has a market cap of 241.8M. Regarding current trading prices, PMEDF is priced at $0.04, while EAPIF trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas EAPIF's P/E ratio is -1.64. In terms of profitability, PMEDF's ROE is +1.24%, compared to EAPIF's ROE of -0.13%. Regarding short-term risk, PMEDF is more volatile compared to EAPIF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check EAPIF's competition here
PMEDF vs IMPZY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, IMPZY has a market cap of 200.8M. Regarding current trading prices, PMEDF is priced at $0.04, while IMPZY trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas IMPZY's P/E ratio is -1.60. In terms of profitability, PMEDF's ROE is +1.24%, compared to IMPZY's ROE of +15.11%. Regarding short-term risk, PMEDF is more volatile compared to IMPZY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check IMPZY's competition here
PMEDF vs VMTHF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, VMTHF has a market cap of 184.7M. Regarding current trading prices, PMEDF is priced at $0.04, while VMTHF trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas VMTHF's P/E ratio is -2.01. In terms of profitability, PMEDF's ROE is +1.24%, compared to VMTHF's ROE of -0.30%. Regarding short-term risk, PMEDF is more volatile compared to VMTHF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check VMTHF's competition here
PMEDF vs DTXMF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, DTXMF has a market cap of 180.6M. Regarding current trading prices, PMEDF is priced at $0.04, while DTXMF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas DTXMF's P/E ratio is -9.52. In terms of profitability, PMEDF's ROE is +1.24%, compared to DTXMF's ROE of -0.74%. Regarding short-term risk, PMEDF is less volatile compared to DTXMF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check DTXMF's competition here
PMEDF vs EKDHF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, EKDHF has a market cap of 151.9M. Regarding current trading prices, PMEDF is priced at $0.04, while EKDHF trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas EKDHF's P/E ratio is 17.58. In terms of profitability, PMEDF's ROE is +1.24%, compared to EKDHF's ROE of +0.08%. Regarding short-term risk, PMEDF is more volatile compared to EKDHF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check EKDHF's competition here
PMEDF vs PXMBF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, PXMBF has a market cap of 149.9M. Regarding current trading prices, PMEDF is priced at $0.04, while PXMBF trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas PXMBF's P/E ratio is 29.17. In terms of profitability, PMEDF's ROE is +1.24%, compared to PXMBF's ROE of +0.01%. Regarding short-term risk, PMEDF is more volatile compared to PXMBF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check PXMBF's competition here
PMEDF vs AVHHL Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, AVHHL has a market cap of 126.7M. Regarding current trading prices, PMEDF is priced at $0.04, while AVHHL trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas AVHHL's P/E ratio is -2.83. In terms of profitability, PMEDF's ROE is +1.24%, compared to AVHHL's ROE of +4.77%. Regarding short-term risk, PMEDF is more volatile compared to AVHHL. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check AVHHL's competition here
PMEDF vs CLLKF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CLLKF has a market cap of 123.3M. Regarding current trading prices, PMEDF is priced at $0.04, while CLLKF trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CLLKF's P/E ratio is -0.90. In terms of profitability, PMEDF's ROE is +1.24%, compared to CLLKF's ROE of -0.50%. Regarding short-term risk, PMEDF is more volatile compared to CLLKF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CLLKF's competition here
PMEDF vs AMEUF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, AMEUF has a market cap of 120.5M. Regarding current trading prices, PMEDF is priced at $0.04, while AMEUF trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas AMEUF's P/E ratio is -1.75. In terms of profitability, PMEDF's ROE is +1.24%, compared to AMEUF's ROE of -1.90%. Regarding short-term risk, PMEDF is less volatile compared to AMEUF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check AMEUF's competition here
PMEDF vs SOMNF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, SOMNF has a market cap of 111.4M. Regarding current trading prices, PMEDF is priced at $0.04, while SOMNF trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas SOMNF's P/E ratio is -51.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to SOMNF's ROE of -0.07%. Regarding short-term risk, PMEDF is more volatile compared to SOMNF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check SOMNF's competition here
PMEDF vs BCCOY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, BCCOY has a market cap of 105.9M. Regarding current trading prices, PMEDF is priced at $0.04, while BCCOY trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas BCCOY's P/E ratio is -0.75. In terms of profitability, PMEDF's ROE is +1.24%, compared to BCCOY's ROE of -0.50%. Regarding short-term risk, PMEDF is less volatile compared to BCCOY. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check BCCOY's competition here
PMEDF vs JMDMF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, JMDMF has a market cap of 94.1M. Regarding current trading prices, PMEDF is priced at $0.04, while JMDMF trades at $3.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas JMDMF's P/E ratio is -13.68. In terms of profitability, PMEDF's ROE is +1.24%, compared to JMDMF's ROE of N/A. Regarding short-term risk, PMEDF is less volatile compared to JMDMF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check JMDMF's competition here
PMEDF vs RSHUF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, RSHUF has a market cap of 91.5M. Regarding current trading prices, PMEDF is priced at $0.04, while RSHUF trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas RSHUF's P/E ratio is -5.81. In terms of profitability, PMEDF's ROE is +1.24%, compared to RSHUF's ROE of -4.12%. Regarding short-term risk, PMEDF is less volatile compared to RSHUF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check RSHUF's competition here
PMEDF vs CKMTF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CKMTF has a market cap of 85.2M. Regarding current trading prices, PMEDF is priced at $0.04, while CKMTF trades at $12.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CKMTF's P/E ratio is -3.32. In terms of profitability, PMEDF's ROE is +1.24%, compared to CKMTF's ROE of +2.58%. Regarding short-term risk, PMEDF is more volatile compared to CKMTF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CKMTF's competition here
PMEDF vs SNZZF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, SNZZF has a market cap of 84.1M. Regarding current trading prices, PMEDF is priced at $0.04, while SNZZF trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas SNZZF's P/E ratio is -5.35. In terms of profitability, PMEDF's ROE is +1.24%, compared to SNZZF's ROE of -0.41%. Regarding short-term risk, PMEDF is more volatile compared to SNZZF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check SNZZF's competition here
PMEDF vs TLTFF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, TLTFF has a market cap of 51.8M. Regarding current trading prices, PMEDF is priced at $0.04, while TLTFF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas TLTFF's P/E ratio is -20.15. In terms of profitability, PMEDF's ROE is +1.24%, compared to TLTFF's ROE of -3.15%. Regarding short-term risk, PMEDF is more volatile compared to TLTFF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check TLTFF's competition here
PMEDF vs BLOZF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, BLOZF has a market cap of 49.6M. Regarding current trading prices, PMEDF is priced at $0.04, while BLOZF trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas BLOZF's P/E ratio is -10.25. In terms of profitability, PMEDF's ROE is +1.24%, compared to BLOZF's ROE of -2.60%. Regarding short-term risk, PMEDF is more volatile compared to BLOZF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check BLOZF's competition here
PMEDF vs BRNHF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, BRNHF has a market cap of 42.1M. Regarding current trading prices, PMEDF is priced at $0.04, while BRNHF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas BRNHF's P/E ratio is -1.33. In terms of profitability, PMEDF's ROE is +1.24%, compared to BRNHF's ROE of -0.09%. Regarding short-term risk, PMEDF is more volatile compared to BRNHF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check BRNHF's competition here
PMEDF vs RDGL Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, RDGL has a market cap of 37.2M. Regarding current trading prices, PMEDF is priced at $0.04, while RDGL trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas RDGL's P/E ratio is -8.18. In terms of profitability, PMEDF's ROE is +1.24%, compared to RDGL's ROE of -1.18%. Regarding short-term risk, PMEDF is more volatile compared to RDGL. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check RDGL's competition here
PMEDF vs NVYTF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, NVYTF has a market cap of 33.9M. Regarding current trading prices, PMEDF is priced at $0.04, while NVYTF trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas NVYTF's P/E ratio is -0.86. In terms of profitability, PMEDF's ROE is +1.24%, compared to NVYTF's ROE of -0.73%. Regarding short-term risk, PMEDF is more volatile compared to NVYTF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check NVYTF's competition here
PMEDF vs POSC Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, POSC has a market cap of 31.8M. Regarding current trading prices, PMEDF is priced at $0.04, while POSC trades at $2.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas POSC's P/E ratio is 0.37. In terms of profitability, PMEDF's ROE is +1.24%, compared to POSC's ROE of -3.78%. Regarding short-term risk, PMEDF is less volatile compared to POSC. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check POSC's competition here
PMEDF vs IPDQF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, IPDQF has a market cap of 28.5M. Regarding current trading prices, PMEDF is priced at $0.04, while IPDQF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas IPDQF's P/E ratio is -1.40. In terms of profitability, PMEDF's ROE is +1.24%, compared to IPDQF's ROE of -0.88%. Regarding short-term risk, PMEDF is more volatile compared to IPDQF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check IPDQF's competition here
PMEDF vs MKEAF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, MKEAF has a market cap of 25.9M. Regarding current trading prices, PMEDF is priced at $0.04, while MKEAF trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas MKEAF's P/E ratio is -4.11. In terms of profitability, PMEDF's ROE is +1.24%, compared to MKEAF's ROE of +0.50%. Regarding short-term risk, PMEDF is more volatile compared to MKEAF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check MKEAF's competition here
PMEDF vs GTHP Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, GTHP has a market cap of 25.1M. Regarding current trading prices, PMEDF is priced at $0.04, while GTHP trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas GTHP's P/E ratio is -6.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to GTHP's ROE of +0.70%. Regarding short-term risk, PMEDF is more volatile compared to GTHP. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check GTHP's competition here
PMEDF vs KBBTF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, KBBTF has a market cap of 24.1M. Regarding current trading prices, PMEDF is priced at $0.04, while KBBTF trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas KBBTF's P/E ratio is -2.30. In terms of profitability, PMEDF's ROE is +1.24%, compared to KBBTF's ROE of N/A. Regarding short-term risk, PMEDF is more volatile compared to KBBTF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check KBBTF's competition here
PMEDF vs PYNKF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, PYNKF has a market cap of 21M. Regarding current trading prices, PMEDF is priced at $0.04, while PYNKF trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas PYNKF's P/E ratio is 3.29. In terms of profitability, PMEDF's ROE is +1.24%, compared to PYNKF's ROE of -2.30%. Regarding short-term risk, PMEDF is less volatile compared to PYNKF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check PYNKF's competition here
PMEDF vs EMITF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, EMITF has a market cap of 20.1M. Regarding current trading prices, PMEDF is priced at $0.04, while EMITF trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas EMITF's P/E ratio is -8.57. In terms of profitability, PMEDF's ROE is +1.24%, compared to EMITF's ROE of -0.14%. Regarding short-term risk, PMEDF is more volatile compared to EMITF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check EMITF's competition here
PMEDF vs DIZTF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, DIZTF has a market cap of 18M. Regarding current trading prices, PMEDF is priced at $0.04, while DIZTF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas DIZTF's P/E ratio is -11.16. In terms of profitability, PMEDF's ROE is +1.24%, compared to DIZTF's ROE of -0.72%. Regarding short-term risk, PMEDF is less volatile compared to DIZTF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check DIZTF's competition here
PMEDF vs ASAPF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ASAPF has a market cap of 16.3M. Regarding current trading prices, PMEDF is priced at $0.04, while ASAPF trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ASAPF's P/E ratio is -20.94. In terms of profitability, PMEDF's ROE is +1.24%, compared to ASAPF's ROE of -0.32%. Regarding short-term risk, PMEDF is more volatile compared to ASAPF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check ASAPF's competition here
PMEDF vs VPTDF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, VPTDF has a market cap of 14.6M. Regarding current trading prices, PMEDF is priced at $0.04, while VPTDF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas VPTDF's P/E ratio is -4.24. In terms of profitability, PMEDF's ROE is +1.24%, compared to VPTDF's ROE of +1.07%. Regarding short-term risk, PMEDF is more volatile compared to VPTDF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check VPTDF's competition here
PMEDF vs TMDIF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, TMDIF has a market cap of 13.9M. Regarding current trading prices, PMEDF is priced at $0.04, while TMDIF trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas TMDIF's P/E ratio is -0.65. In terms of profitability, PMEDF's ROE is +1.24%, compared to TMDIF's ROE of +8.70%. Regarding short-term risk, PMEDF is less volatile compared to TMDIF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check TMDIF's competition here
PMEDF vs ATBPF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ATBPF has a market cap of 11.4M. Regarding current trading prices, PMEDF is priced at $0.04, while ATBPF trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ATBPF's P/E ratio is -0.86. In terms of profitability, PMEDF's ROE is +1.24%, compared to ATBPF's ROE of -0.40%. Regarding short-term risk, PMEDF is more volatile compared to ATBPF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check ATBPF's competition here
PMEDF vs LXXGF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, LXXGF has a market cap of 11.3M. Regarding current trading prices, PMEDF is priced at $0.04, while LXXGF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas LXXGF's P/E ratio is -0.85. In terms of profitability, PMEDF's ROE is +1.24%, compared to LXXGF's ROE of -1.23%. Regarding short-term risk, PMEDF is more volatile compared to LXXGF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check LXXGF's competition here
PMEDF vs RMSL Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, RMSL has a market cap of 10.2M. Regarding current trading prices, PMEDF is priced at $0.04, while RMSL trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas RMSL's P/E ratio is 0.63. In terms of profitability, PMEDF's ROE is +1.24%, compared to RMSL's ROE of -12.31%. Regarding short-term risk, PMEDF is more volatile compared to RMSL. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check RMSL's competition here
PMEDF vs ALRTF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ALRTF has a market cap of 9M. Regarding current trading prices, PMEDF is priced at $0.04, while ALRTF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ALRTF's P/E ratio is -0.35. In terms of profitability, PMEDF's ROE is +1.24%, compared to ALRTF's ROE of +0.52%. Regarding short-term risk, PMEDF is less volatile compared to ALRTF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check ALRTF's competition here
PMEDF vs PLLWF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, PLLWF has a market cap of 8M. Regarding current trading prices, PMEDF is priced at $0.04, while PLLWF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas PLLWF's P/E ratio is -0.66. In terms of profitability, PMEDF's ROE is +1.24%, compared to PLLWF's ROE of -0.99%. Regarding short-term risk, PMEDF is less volatile compared to PLLWF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check PLLWF's competition here
PMEDF vs USAQ Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, USAQ has a market cap of 7M. Regarding current trading prices, PMEDF is priced at $0.04, while USAQ trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas USAQ's P/E ratio is -15.51. In terms of profitability, PMEDF's ROE is +1.24%, compared to USAQ's ROE of +0.63%. Regarding short-term risk, PMEDF is more volatile compared to USAQ. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check USAQ's competition here
PMEDF vs MDXHF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, MDXHF has a market cap of 6.9M. Regarding current trading prices, PMEDF is priced at $0.04, while MDXHF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas MDXHF's P/E ratio is -2.10. In terms of profitability, PMEDF's ROE is +1.24%, compared to MDXHF's ROE of +0.58%. Regarding short-term risk, PMEDF is less volatile compared to MDXHF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check MDXHF's competition here
PMEDF vs NGMDF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, NGMDF has a market cap of 5.9M. Regarding current trading prices, PMEDF is priced at $0.04, while NGMDF trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas NGMDF's P/E ratio is -2.58. In terms of profitability, PMEDF's ROE is +1.24%, compared to NGMDF's ROE of +0.34%. Regarding short-term risk, PMEDF is more volatile compared to NGMDF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check NGMDF's competition here
PMEDF vs QLIS Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, QLIS has a market cap of 5.5M. Regarding current trading prices, PMEDF is priced at $0.04, while QLIS trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas QLIS's P/E ratio is 2.22. In terms of profitability, PMEDF's ROE is +1.24%, compared to QLIS's ROE of -0.60%. Regarding short-term risk, PMEDF is more volatile compared to QLIS. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check QLIS's competition here
PMEDF vs RHNMF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, RHNMF has a market cap of 5.4M. Regarding current trading prices, PMEDF is priced at $0.04, while RHNMF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas RHNMF's P/E ratio is -0.95. In terms of profitability, PMEDF's ROE is +1.24%, compared to RHNMF's ROE of +15.91%. Regarding short-term risk, PMEDF is less volatile compared to RHNMF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check RHNMF's competition here
PMEDF vs BIEL Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, BIEL has a market cap of 5.4M. Regarding current trading prices, PMEDF is priced at $0.04, while BIEL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas BIEL's P/E ratio is N/A. In terms of profitability, PMEDF's ROE is +1.24%, compared to BIEL's ROE of +0.05%. Regarding short-term risk, PMEDF is less volatile compared to BIEL. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check BIEL's competition here
PMEDF vs CYDX Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, CYDX has a market cap of 5.1M. Regarding current trading prices, PMEDF is priced at $0.04, while CYDX trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas CYDX's P/E ratio is 1.28. In terms of profitability, PMEDF's ROE is +1.24%, compared to CYDX's ROE of +0.14%. Regarding short-term risk, PMEDF is more volatile compared to CYDX. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check CYDX's competition here
PMEDF vs ADMT Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ADMT has a market cap of 4.7M. Regarding current trading prices, PMEDF is priced at $0.04, while ADMT trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ADMT's P/E ratio is -7.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to ADMT's ROE of -0.01%. Regarding short-term risk, PMEDF is more volatile compared to ADMT. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check ADMT's competition here
PMEDF vs ODYY Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ODYY has a market cap of 4.1M. Regarding current trading prices, PMEDF is priced at $0.04, while ODYY trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ODYY's P/E ratio is -4.12. In terms of profitability, PMEDF's ROE is +1.24%, compared to ODYY's ROE of +0.18%. Regarding short-term risk, PMEDF is more volatile compared to ODYY. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check ODYY's competition here
PMEDF vs VYCO Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, VYCO has a market cap of 3.7M. Regarding current trading prices, PMEDF is priced at $0.04, while VYCO trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas VYCO's P/E ratio is -11.00. In terms of profitability, PMEDF's ROE is +1.24%, compared to VYCO's ROE of +0.00%. Regarding short-term risk, PMEDF is more volatile compared to VYCO. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check VYCO's competition here
PMEDF vs VANIW Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, VANIW has a market cap of 3.4M. Regarding current trading prices, PMEDF is priced at $0.04, while VANIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas VANIW's P/E ratio is N/A. In terms of profitability, PMEDF's ROE is +1.24%, compared to VANIW's ROE of -2.94%. Regarding short-term risk, PMEDF is less volatile compared to VANIW. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check VANIW's competition here
PMEDF vs FZMD Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, FZMD has a market cap of 3M. Regarding current trading prices, PMEDF is priced at $0.04, while FZMD trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas FZMD's P/E ratio is 1.33. In terms of profitability, PMEDF's ROE is +1.24%, compared to FZMD's ROE of +0.13%. Regarding short-term risk, PMEDF is more volatile compared to FZMD. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check FZMD's competition here
PMEDF vs TBRIF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, TBRIF has a market cap of 2.4M. Regarding current trading prices, PMEDF is priced at $0.04, while TBRIF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas TBRIF's P/E ratio is -0.82. In terms of profitability, PMEDF's ROE is +1.24%, compared to TBRIF's ROE of +16.81%. Regarding short-term risk, PMEDF is more volatile compared to TBRIF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check TBRIF's competition here
PMEDF vs LLBO Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, LLBO has a market cap of 2.2M. Regarding current trading prices, PMEDF is priced at $0.04, while LLBO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas LLBO's P/E ratio is N/A. In terms of profitability, PMEDF's ROE is +1.24%, compared to LLBO's ROE of +0.00%. Regarding short-term risk, PMEDF is more volatile compared to LLBO. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check LLBO's competition here
PMEDF vs ESMC Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ESMC has a market cap of 1.9M. Regarding current trading prices, PMEDF is priced at $0.04, while ESMC trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ESMC's P/E ratio is -12.50. In terms of profitability, PMEDF's ROE is +1.24%, compared to ESMC's ROE of -125.28%. Regarding short-term risk, PMEDF is more volatile compared to ESMC. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check ESMC's competition here
PMEDF vs VRSEF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, VRSEF has a market cap of 1.4M. Regarding current trading prices, PMEDF is priced at $0.04, while VRSEF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas VRSEF's P/E ratio is 0.14. In terms of profitability, PMEDF's ROE is +1.24%, compared to VRSEF's ROE of +1.00%. Regarding short-term risk, PMEDF is less volatile compared to VRSEF. This indicates potentially lower risk in terms of short-term price fluctuations for PMEDF.Check VRSEF's competition here
PMEDF vs KLYG Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, KLYG has a market cap of 1.4M. Regarding current trading prices, PMEDF is priced at $0.04, while KLYG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas KLYG's P/E ratio is -11.33. In terms of profitability, PMEDF's ROE is +1.24%, compared to KLYG's ROE of -1.40%. Regarding short-term risk, PMEDF is more volatile compared to KLYG. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check KLYG's competition here
PMEDF vs NUMD Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, NUMD has a market cap of 1.3M. Regarding current trading prices, PMEDF is priced at $0.04, while NUMD trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas NUMD's P/E ratio is 1.53. In terms of profitability, PMEDF's ROE is +1.24%, compared to NUMD's ROE of +0.23%. Regarding short-term risk, PMEDF is more volatile compared to NUMD. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check NUMD's competition here
PMEDF vs UAHC Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, UAHC has a market cap of 1.1M. Regarding current trading prices, PMEDF is priced at $0.04, while UAHC trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas UAHC's P/E ratio is 0.54. In terms of profitability, PMEDF's ROE is +1.24%, compared to UAHC's ROE of +0.04%. Regarding short-term risk, PMEDF is more volatile compared to UAHC. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check UAHC's competition here
PMEDF vs ELXMF Comparison February 2026
PMEDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PMEDF stands at 7.9M. In comparison, ELXMF has a market cap of 541.2K. Regarding current trading prices, PMEDF is priced at $0.04, while ELXMF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PMEDF currently has a P/E ratio of -1.90, whereas ELXMF's P/E ratio is -0.06. In terms of profitability, PMEDF's ROE is +1.24%, compared to ELXMF's ROE of -0.50%. Regarding short-term risk, PMEDF is more volatile compared to ELXMF. This indicates potentially higher risk in terms of short-term price fluctuations for PMEDF.Check ELXMF's competition here